0 Cyprotex plc Analyst Ratings, Earnings, Dividends and Insider Trades | $CRX | LON:CRX | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Cyprotex plc Company Profile (LON:CRX) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileToday's Chart Consensus Ratings for Cyprotex plc (LON:CRX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: No ratings tracked in the last 12 months.Consensus Rating:N/A (Score: NaN)Consensus Price Target: N/A Analysts' Ratings History for Cyprotex plc (LON:CRX) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare1/23/2014N+1 SingerReiterated RatingCorporateView 1/2/2014N+1 SingerReiterated RatingCorporateView 9/27/2013N+1 SingerReiterated RatingCorporate -> CorporateView 8/7/2013N+1 SingerReiterated RatingCorporate -> CorporateView 7/18/2013N+1 SingerReiterated RatingCorporate -> CorporateView 6/20/2013N+1 SingerReiterated RatingCorporate -> CorporateView 4/16/2013N+1 SingerReiterated RatingCorporate -> CorporateView (Data available from 3/10/2012 forward) Earnings History for Cyprotex plc (LON:CRX)No earnings announcements for this company have been tracked by Analyst Ratings Network Dividend History for Cyprotex plc (LON:CRX)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Cyprotex plc (LON:CRX)No insider trades for this company have been tracked by Analyst Ratings Network About Cyprotex plc Cyprotex PLC (Cyprotex) is a holding company specializing in preclinical ADME Tox, both in vitro (laboratory experiments) and in silico (computer modelling). The principal activities of the Company, along with its subsidiaries, are that of providing in vitro and in silico Absorption, Distribution, Metabolism, Excretion, Toxicity and Pharmacokinetics (ADMET and PK) information to the pharmaceutical and biotechnology industries. The Company's in vitro ADME and DMPK services include in vitro metabolism, in vitro permeability and transporters, solubility and physicochemical properties, in vitro protein binding and PK and bioanalysis. Cyprotex serves drug-discovery organizations, which include pharmaceutical companies, small virtual companies, as well as academic and not-for-profit laboratories. It also supports the research efforts of the cosmetic and agrochemical industries, principally for in vitro toxicity testing. Its subsidiaries are Cyprotex Discovery Limited and Apredica, LLC. Industry, Sector and Symbol: Sector: N/A Industry: N/A Sub-Industry: N/A Exchange: LON Symbol: CRX CUSIP: Key Metrics: Previous Close: $0.0050 Day Moving Average: $N/A200 Day Moving Average: $N/A P/E Ratio: N/AP/E Growth: N/AMarket Cap: $N/ACurrent Quarter EPS Consensus Estimate: $N/A EPS Additional Links: View CRX on Google FinanceView CRX on Yahoo FinanceView CRX's Company Profile on ReutersSearch for Cyprotex plc on Google Cyprotex plc (LON:CRX) Chart for Monday, March, 10, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.